The ErbB/HER receptor protein-tyrosine kinases and cancer

Biochemical and Biophysical Research Communications

Volumn 319, Issue 1, 2004, Pages 1-11

  Roskoski Jr , Robert ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bcr Abl; Breast cancer; Cetuximab; Chronic myelogenous leukemia; Colorectal cancer; CP 358, 774; Epidermal growth factor; Erbitux; ERK; Erlotinib; Gefitinib; Gleevec; Herceptin; IMC C225; Irressa; K ras; MEK; Monoclonal antibody; Non small cell lung cancer; OSI 774

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; GROWTH FACTOR; IRINOTECAN; QUINAZOLINE DERIVATIVE; TRASTUZUMAB; TUNICAMYCIN;

ACNE; AUTOPHOSPHORYLATION; BREAST CANCER; CANCER; CARDIOTOXICITY; CHROMOSOME; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CYTOPLASM; DIMERIZATION; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; GENE MUTATION; HEAD CANCER; HUMAN; IC 50; LETHALITY; LUNG NON SMALL CELL CANCER; NECK CANCER; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOPLASM; DIMERIZATION; ENZYME INHIBITORS; GLYCOPROTEINS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MUTATION; NEOPLASMS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 2442701289     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.04.150     Document Type: Review

References (51)

1. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 103:2000;211-225
2. Available from 〈http://www.nobel.se/medicine/laureates/1986/cohen- lecture.html〉
3. Burgess A.W., Cho H.S., Eigenbrot C., Ferguson K.M., Garrett T.P., Leahy D.J., Lemmon M.A., Sliwkowski M.X., Ward C.W., Yokoyama S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell. 12:2003;541-552. A superb summary of the X-ray crystallographic structures of the ErbB family
4. Stamos J., Sliwkowski M.X., Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277:2002;46265-46272
5. Cohen P. The role of protein phosphorylation in human health and disease. Eur. J. Biochem. 268:2001;5001-5010
6. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science. 298:2002;1912-1934
7. Roskoski R. Jr. STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochem. Biophys. Res. Commun. 309:2003;709-717
8. Hunter T., Sefton B.M. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc. Natl. Acad. Sci. USA. 77:1980;1311-1315
9. Blume-Jensen P., Hunter T. Oncogenic kinase signaling. Nature. 411:2001;355-365. A comprehensive review of protein-tyrosine kinases implicated in cancer
10. Chinkers M., Cohen S. Purified EGF receptor-kinase interacts specifically with antibodies to Rous sarcoma virus transforming protein. Nature. 290:1981;516-519. The first description of a receptor protein-tyrosine kinase that includes a summary of how the EGF receptor was thought initially to be a protein-threonine kinase
11. Cohen S., Ushiro H., Stoscheck C., Chinkers M. A native 170, 000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J. Biol. Chem. 257:1982;1523-1531
12. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Ann. Rev. Biochem. 56:1987;881-914
13. Downward J., Yarden Y., Mayes E., Scrace G., Totty N., Stockwell P., Ullrich A., Schlessinger J., Waterfield M.D. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 307:1984;521-527
14. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19:1995;183-232
15. Yarden Y., Sliwkowski M.X. Untangling the erbB signaling network. Nat. Rev. (Mol. Cell. Biol.). 2:2001;127-137
16. Harris R.C., Chung E., Coffey R.J. EGF receptor ligands. Exp. Cell Res. 284:2003;2-13
17. Jorissen R.N., Walker F.W., Pouliot N., Garrett T.P.J., Ward C.W., Burgess A.W. Epidermal growth factor receptor: mechanisms of activation and signaling. Exp. Cell Res. 284:2003;31-53
18. Yarden Y., Schlessinger J. Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. Biochemistry. 26:1987;1434-1442
19. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16:1997;1647-1655
20. Citri A., Skaria K.B., Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp. Cell Res. 284:2003;54-65
21. Carpenter G. ErbB-4: mechanism of action and biology. Exp. Cell Res. 284:2003;66-77
22. Ullrich A., Coussens L., Hayflick J.S., Dull T.J., Gray A., Tam A.W., Lee J., Yarden Y., Libermann T.A., Schlessinger J., Downward J., Mayes E.L.V., Whittle N., Waterfield M.D., Seeburg P.H. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 309:1984;418-425. The first description of the topology of receptor protein-tyrosine kinases including a single transmembrane spanning segment, a novelty at the time
23. Guy P.M., Platko J.V., Cantley L.C., Cerione R.A., Carraway III K.L. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA. 91:1994;8132-8136
24. Lemmon M.A., Bu Z., Ladbury J.E., Zhou M., Pinchasi D., Lax I., Engelman D.M., Schlessinger J. Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J. 16:1997;281-294
25. Garrett T.P.J., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Zhu H.J., Walker F., Frenkel M.J., Hoyne P.A., Jorissen R.N., Nice E.C., Burgess A.W., Ward C.W. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor-α Cell. 110:2002;763-773
26. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., Saito K., Sakamoto A., Inoue M., Shirouzu M., Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell. 110:2002;775-787
27. Cho H.S., Leahy D.J. Structure of the extracellular region of HER3 reveals an interdomain tether. Science. 297:2002;1330-1333
28. Ferguson K.M., Berger M.B., Mendrola J.M., Cho H.-S., Leahy D.J., Lemmon M.A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell. 11:2003;507-517
29. Garrett T.P.J., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Kofler M., Jorissen R.N., Nice E.C., Burgess A.W., Ward C.W. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell. 11:2003;495-505
30. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W. Jr., Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 421:2003;756-760
31. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:2001;783-792
32. HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA. 89:1992;4285-4289
33. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61:2001;4744-4749
34. Dancey J., Sausville E.A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Dis. 2:2003;296-313
35. Taylor S.S., Radzio-Andzelm E., Hunter T. How do protein kinases discriminate between serine/threonine and tyrosine? Structural insights from the insulin receptor protein-tyrosine kinase. FASEB J. 9:1995;1255-1266
36. Hanks S.K., Quinn A.M., Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science. 241:1988;42-52
37. Zheng J., Knighton D.R., Ten Eyck L.F., Karlsson R., Xuong N., Taylor S.S., Sowadski J.M. Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor. Biochemistry. 32:1993;2154-2161
38. ′ -monophosphate dependent protein kinase: kinetic mechanism for the bovine skeletal muscle catalytic subunit Biochemistry. 21:1982;5794-5799
39. Brignola P.S., Lackey K., Kadwell S.H., Hoffman C., Horne E., Carter H.L., Stuart J.D., Blackburn K., Moyer M.B., Alligood K.J., Knight W.B., Wood E.R. Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors. J. Biol. Chem. 277:2002;1576-1585
40. Hubbard S.R., Till J.H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 69:2000;373-398
41. Huse M., Kuriyan J. The conformational plasticity of protein kinases. Cell. 109:2002;275-282
42. Gotoh N., Tojo A., Hino M., Yazaki Y., Shibuya M. A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor. Biochem. Biophys. Res. Commun. 186:1992;768-774
43. Fry D.W. Mechanism of action of ErbB tyrosine kinase inhibitors. Exp. Cell Res. 284:2003;131-139
44. Barker A.J., Gibson K.H., Grundy W., Godfrey A.A., Barlow J.J., Healy M.P., Woodburn J.R., Ashton S.E., Curry B.J., Scarlett L., Henthorn L., Richards L. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett. 11:2001;1911-1914
45. Cohen M.H., Williams G.A., Sridhara R., Chen G., McGuinn W.D. Jr., Morse D., Abraham S., Rahman A., Liang C., Lostritto R., Baird A., Pazdur R. United States Food and Drug Administration Drug Approval Summary: Gefitinib (ZD1839; Iressa) Tablets. Clin. Cancer Res. 10:2004;1212-1218
46. Moyer J.D., Barbacci E.G., Iwata K.K., Arnold L., Boman B., Cunningham A., DiOrio C., Doty J., Morin M.J., Moyer M.P., Neveu M., Pollack V.A., Pustilnik L.R., Reynolds M.M., Sloan D., Theleman A., Miller P. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57:1997;4838-4848
47. Fernandes H., Cohen S., Bishayee S. Glycosylation-induced conformational modification positively regulates receptor-receptor association. J. Biol. Chem. 276:2001;5375-5383
48. Baulida J., Kraus M.H., Alimandi M., Di Fiore P.P., Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem. 271:1996;5251-5257
49. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70
50. Minna J.D., Roth J.A., Gazdar A.F. Focus on lung cancer. Cancer Cell. 1:2002;1-8
51. Burnett G., Kennedy E.P. The enzymatic phosphorylation of proteins. J. Biol. Chem. 211:1954;969-980